Project Overview
- Drug concept: Develop a small molecule for cancer immunotherapy that targets immunosuppressive cell trafficking to increase ICT response rate
- Target class: EVT801 is a specific inhibitor of the tyrosine kinase VEGFR3
- Project status: Drug candidate / 1 year from phase I
- Targeted indication: Combination with immune checkpoint therapies for non-responder patients
- Administration: Oral administration
1 Evotec, Toulouse, France
2 Sanofi, Lyon, France
